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Abstract
Background: Dendritic cells (DCs) are antigen presenting cells capable of inducing specific immune responses
against microbial infections, transplant antigens, or tumors. Interestingly, microenvironment conditions such as
those present in tumor settings might induce a DC phenotype that is poorly immunogenic and with the capability
of promoting angiogenesis. We hypothesize that this plasticity may be caused not only by the action of specific
cytokines or growth factors but also by the properties of the surfaces with which they interact, such as extracellular
matrix (ECM) components.
Results: Herewith we studied the effect of different surfaces and soluble factors on the biology of DCs. To
accomplish this, we cultured murine myeloid(m) DCs on surfaces coated with fibronectin, collagen I, gelatin, and
Matrigel using poly-D-lysine and polystyrene as non-biological surfaces. Further, we cultured these cells in the
presence of regular DC medium (RPMI 10% FBS) or commercially available endothelial medium (EGM-2). We
determined that mDCs could be kept in culture up to 3 weeks in these conditions, but only in the presence of
GM-CSF. We were able to determine that long-term DC cultures produce an array of angiogenic factors, and that
some of these cultures still retain the capability to induce T cell responses.
Conclusions: Altogether these data indicate that in order to design DC-based vaccines or treatments focused on
changing the phenotype of DCs associated with diseases such as cancer or atherosclerosis, it becomes necessary
to fully investigate the microenvironment in which these cells are present or will be delivered.
Background
Dendritic cells (DCs) are professional antigen presenting
cells (APCs) found in peripheral tissues and in immunolo-
gical organs such as thymus, bone marrow, spleen, lymph
nodes and Peyer’s patches [1-3]. In the mouse, DCs can be
broadly divided into plasmacytoid and myeloid DCs [4].
Plasmacytoid DCs (pDCs) are characterized by the expres-
sion of B220 but no CD11b and produce large amounts of
type-1 interferon in response to viral infections [5,6]. On
the other hand, bone marrow-derived DCs (myeloid DCs)
are present in most tissues and are characterized by coex-
pression of CD11c and CD11b markers. As reviewed by
Breckpot et al. (2009), these DCs respond to GM-CSF and
are capable of producing IL-12 in response to toll-like
receptor ligands. Interestingly, DCs have been shown to
possess a remarkable cellular plasticity. For example,
pDCs could acquire myeloid DC characteristics under the
influence of viral infection [5].
In order to elicit productive T cells responses, DC
major histocompatibility (MHC)/peptide complexes must
interact with specific T cell receptors (Signal 1) in the
context of an appropriate costimulatory molecule inter-
action between both cell types (Signal 2). It has been
recently considered that the microenvironment where
this interaction occurs (Signal 3) will determine the fate
the subsequent immune response towards an immuno-
genic or tolerogenic response [4]. A clear example of the
relevance of the microenvironment on DC biology can be
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tumor milieu such as vascular endothelial growth factor
(VEGF), interleukin (IL)-10 and prostaglandin-2 (PGE-2)
can profoundly affect the biology of DCs making them
immunosuppressive, incapable of inducing specific
immune responses or capable of inducing regulatory T
cells [7,8]. In particular, DCs showing low levels of costi-
mulatory molecules have been detected in microenviron-
ments characterized by high levels of VEGF [9]. These
DCs, showing highly immunosuppressive properties, are
able to render T cells anergic or tolerised, thus abrogat-
ing immune responses. On the contrary, endothelial cell-
produced antiangiogenic cytokine vascular endothelial
growth inhibitor induces DC maturation [10]. Further-
more, treatment of the tolerogenic DCs with inflamma-
tory molecules, render immunogenic DCs with the
capability to activate T cells [11]. Besides an immune
“paralysis”, we and others have shown that DCs, or leu-
kocytes expressing DC markers are able to produce
angiogenic factors and can promote angiogenesis [12-15].
We hypothesized that this plasticity might be caused
not only by the action of specific cytokines or growth
factors, but also by the interaction of these cells with
extracellular matrix (ECM) components. Herewith, we
performed a series of studies in order to determine the
influence of different surfaces and growth factors on the
biological properties of myeloid DCs.
Methods
Animals
Six to eight week old female C57BL/6 (H-2Kb) and
BALB/c (H-2Kd) mice (Charles River Laboratories, Wil-
mington, MA) were used in protocols approved by the
Institutional Animal Care and Use Committee at Ohio
University.
In vitro generation and maturation of murine DCs
Murine DCs were generated from bone marrow precur-
sors recovered from femurs and tibiae of 6-8 week old
female C57BL/6 mice by the method of Lutz et al.
[16,17]. Briefly, bone marrow cells were dispersed by vig-
orous pipetting and cultured in RPMI-1640 supplemen-
ted with penicillin (100 μg/ml), streptomycin (100 U/ml),
L-glutamine (2 mM) and 10% heat-inactivated fetal
bovine serum (FBS) (all Invitrogen, Carlsbad, CA) in the
presence of 20 ng/ml of recombinant mouse granulocyte-
macrophage colony-stimulating factor (GM-CSF, 315-03,
Peprotech Inc., Rocky Hill, NJ) for 8 days. GM-CSF was
replenished on days 3 and 6. In some experiments,
maturation was induced by culturing the cells for 2 days
in the presence of 5 ng/ml GM-CSF, 20 ng/ml mouse
tumor necrosis factor alpha (TNF-a,3 1 5 - 0 1 A ,P e p r o -
tech) and 100 ng/ml bacterial lipopolysaccharide (LPS
from E. coli, serotype 0111:B4, L2630, Sigma).
Cell lines and tumors
In some experiments we used the murine ID8-Vegf-A cell
line of ovarian cancer [18]. The ID8 cell line is a tumor
cell line derived from spontaneous in vitro malignant
transformation of C57BL/6 mouse ovarian surface epithe-
lial cells originally generated by Roby et al. [19]. This line
has been engineered to express high levels of VEGF-A
(VEGF-164) [20]. These cells were maintained in DMEM
supplemented with 2 mM L-glutamine, 100 μg/ml penicil-
lin, 100 U/ml streptomycin, and 10% heat-inactivated fetal
bovine serum (FBS) (all Invitrogen). Ectopic ID8-Vegf-A
solid ovarian tumors were initiated in C57BL/6 mice by
subcutaneous injection of 7 × 10
6 tumor cells [20,21].
Culture of DCs on different surfaces
In order to investigate the effect of different surfaces on
the biology of DCs, these cells were seeded on commer-
cially available 6-well plates coated with different extracel-
lular matrix components such as fibronectin, collagen I,
gelatin, Matrigel or synthetic poly-D-Lysine (all BD Bios-
ciences, San Jose, CA). Controls included cells cultured on
regular polystyrene tissue culture plates (Corning Costar,
Corning, NY). DCs were seeded on these plates at a con-
centration of 5 × 10
5 cells/ml in either RPMI 10% FBS or
endothelial EBM-2 medium with supplements (EGM2-
MV BulletKit, Lonza) with or without the addition of GM-
CSF (3 ng/ml). Cells were cultured up to 3 weeks in these
conditions and media was replenished once a week. Pic-
tures of live cells were obtained with an inverted micro-
scope attached to a Motic 2000 Camera (Motic,
Richmond, British Columbia, Canada). In order to perform
specific studies, after different times in culture cell super-
natants were collected, surfaces washed with PBS and
attached cells recovered by using cell scrapers.
In order to investigate the effect of tumor-derived GM-
C S Fo nD C s ,w ep r e p a r e dt u m o rc o n d i t i o n e dm e d i u m .
To accomplish this, ID8-Vegf-A cells were cultured until
80% confluence and supernatants collected and filtered.
Then, these supernatants were mixed with RPMI med-
ium (30:70; conditioned medium:RPMI) and used to cul-
ture DCs for 1 week. As a control of GM-CSF specificity
we also cultured these cells in the presence of anti-GM-
CSF receptor antibody (rabbit polyclonal, sc25472, Santa
Cruz Biotechnology Inc. Santa Cruz, CA) as previously
described [22] or isotype control.
Purification of CD11c by means of magnetic sorting
In some experiments CD11c cells were recovered from the
cultures by magnetic sorting. To accomplish this, cells
were mechanically detached from the culture plates by
using cell scrapers. After blocking Fc receptors with anti-
CD16/CD32 antibody (Fc block, 2.4G2; BD Pharmingen,
San Diego, CA), cells were labeled with anti-CD11c mag-
netic beads (MACS Miltenyi, Auburn, CA) and positive
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octoMACS magnet (all MACS Miltenyi) following the
manufacturer’s instructions.
Flow cytometry
Cells were subjected to three-color flow cytometry on a
FACSort flow cytometer using CellQuest 3.2.1f1 software.
(Becton Dickinson, San Jose, CA). We collected 10.000
events per sample. Non-specific staining was blocked with
Fc block in FACS buffer (PBS with 2% FBS and 0.05%
sodium azide). Fluorochrome-conjugated monoclonal
antibodies against CD45 (30-F11), CD11c (HL3), CD80
(16-10A1), CD86 (GL1), MHC-II (KH74), CD54 (3E2),
CD11b (M1/70), GR1 (RB6-8C5), CD40 (3/23), PSGL-1
(2PHI), (all BD Biosciences, San Diego, CA); CD29
(HMb1-1), CD49b (DX5), CD49d (R1-2), CD49e (HMa5-
1), CD49f (GoH3), CD41 (MWReg30), CD51 (RMV-7),
CD61 (2C9.G3), OX40-L (RM134L), CD44 (IM7), CD18
(M18/2), (all eBioscience, San Diego, CA); and CD49a
(HMalpha1, AbD Serotec, Raleigh, NC) were used at 1/
100 dilution.
RT-PCR and Real-Time Quantitative Reverse Transcription-
PCR
RNA was isolated with TRIzol (Invitrogen) and then
reverse transcribed by using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA) following the manufacturer’s instructions. All
RNA samples were treated with DNAse in order to
eliminate possible contaminating genomic DNA. For
qualitative PCR analysis, the PCR cycling was conducted
with Taq polymerase at 94°C (30 s), 57°C (30 s), and
72°C (20 s) for 40 cycles. Expression of specific mole-
cules was also analyzed at the level of RNA by means of
quantitative real time RT-PCR (qPCR) analysis. For
qPCR experiments, we used the absolute quantification
method by generating standard curves for our genes of
interest, and housekeeping gene. We normalized the
cDNA load to mouse glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). Data were expressed as relative
units to GAPDH mRNA molecules. In these assays, we
used (PerfeCTa SYBR Green FastMix, Quantas Bios-
ciences) for detection of the PCR reaction. Each amplifi-
cation experiment was performed in 96-well optical
grade PCR plates covered with optical film) in an iCy-
cler iQ5 real-time PCR instrument (Bio-Rad Labora-
tories, Hercules, CA).
Primers are described in Table 1. All the primers were
designed with the public web Primer 3 program in
order to generate PCR products that cross introns and
ranging between 85 and 115 bp of length. We have used
this program to design the primers described in our pre-
vious publications [12,21,23,24].
Table 1 List of primers used for qualitative and
quantitative PCR studies
Target Gene Primer Sequence
CD29 Forward 5’-CAA ATG CCA AAT CTT GCG GAG A-3’
Reverse 5’-GCA TTC CTT CTT GCA AAA ATG TCG T-3’
CD49a Forward 5’-GAG AGA GAG ATC AAT GCC TTG TGT GAA-3’,
Reverse 5’-CGG ATT GGT GAC TAA AGT TGA TCC AAA-3’
CD49b Forward 5’-CCC TGT GGA CCT ACC CAC TGC-3’,
Reverse 5’-TGA GGG TCA ATC CCA GGC TCA-3’
CD49c Forward 5’-GGG AGC CTG TCG GAC CAC AT-3’,
Reverse 5’-AAA GCG CAG GGT CCA ACA CA-3’
CD49d Forward 5’-TGG AGA AAA TTT TGC ATC ATG TCA AGC-3’,
Reverse 5’-CGG TGC CAG TCC AGT ACG ATG-3’
CD49e Forward 5’-TTG GGG GAC CTG GAC CAA GA-3’,
Reverse 5’-TGG GCC TCC CGG GAA TAT AAA-3’
CD49f Forward 5’-CGG GAG CCT CTT CGG CTT CT-3’
Reverse 5’-CTG CAG CGG GAG TGC TTC TG-3’
CD41 Forward 5’-GTC GCG CCA ACA CCA TGA G-3’
Reverse 5’-GGG TCA CCG CCA AGC TGA AG-3’
CD51 Forward 5’-CCA CCA GTG GTT TGG AGC CTC T-3’
Reverse 5’-TCC AAC TGG CTC TCT CTC CTG CT-3’
CD61 Forward 5’-TGA CGC CAT CAT GCA GGC TA-3’
Reverse 5’-TGG GTC TTG GCA TCC GTG GT-3’
bFGF Forward 5’-TGT GTG CCA ACC GGT ACC TT-3’
Reverse 5’-TTC CAG TCG TTC AAA GAA GAA ACA-3’
GM-CSF Forward 5’-CAT GCC TGT CAC GTT GAA TGA AGA-3’
Reverse 5’-TCA GGC GGG TCT GCA CAC AT-3’
GAPDH Forward 5’-CCT GCA CCA CCA ACT GCT TA-3’
Reverse 5’-CAT GAG TCC TTC CAC GAT ACC A-3’
Heparanase Forward 5’-GGG GCC GGA TGG ATT ACT TT-3’
Reverse 5’ -CCA TGA AAA ACC CGT CTC CA-3’
HGF Forward 5’-GGG ACG GTA TCC ATC ACT AAG A-3’
Reverse 5’-CTT TAC CGC GAT AGC TCG AA-3’
MMP2 Forward 5’-GCA TCG CTC AGA TCC GTG GT-3’
Reverse 5’-GAA TGT GGC CAC CAG CAA GG-3’
MMP9 Forward 5’-TAA AGG CCG CTC GGA TGG TT-3’
Reverse 5’-CCA ACT ACG GTC GCG TCC AC-3’
PIGF Forward 5’-CCT AGC TGG GTT GGC TGT GCA T-3’
Reverse 5’-GCT GCG ACC CCA CAC TTC GT-3’
TWEAK Forward 5’-CCG AGC TAT TGC AGC CCA TT-3’
Reverse 5’-GCC ACT CAC TGT CCC ATC CA-3’
VEGFa164 Forward 5’-GCC AGC ACA TAG AGA GAA TGA GC-3’
Reverse 5’-CAA GGC TCA CAG TGA TTT TCT GG-3’
VEGF-B Forward 5’-CGC CTG CTG CTT GTT GCA CT-3’
Reverse 5’-TCC ATG GCA CCA CTT TCT TCT GG-3’
VEGFR1 Forward 5’-TCA TGC AAG CAG GCC AGA CTC TC-3’
Reverse 5’-CCT TTT GTC CTC CTG GCT CAC G-3’
VEGFR2 Forward 5’-GGG CTT GAT TTC ACC TGGC ACT C-3’
Reverse 5’-CGC CAC AGT CCC AGG AAA GG-3’
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Solid tumor samples were snap-frozen in OCT medium
(Tissue Tek, Sakura, Torrance, CA) and sections were
prepared using a Leica CM1950 Cryostat (Leica Micro-
systems, Bannockburn, IL). Sections were fixed in cold
acetone for 10 minutes, pretreated with 3% H2O2 for 20
min to block endogenous peroxidase activity and
blocked in normal horse serum (Vector Laboratories).
Biotinylated rat anti-mouse CD11c (HL3) and biotiny-
lated hamster isotype control (both BD Pharmingen)
were used at 1:50 dilution for these studies. Then, the
Vectastain ABC kit was applied as described by the
manufacturer (Vector Laboratories). Sections were coun-
terstained with Gill’s hematoxylin (Vector Laboratories).
Images were acquired through a Micropublisher 5.0
Digital CCD Color Camera (Qimaging, Surrey, BC
Canada).
ELISA analysis
The concentration of different cytokines in culture super-
natants was quantified by antigen capture ELISA. We
used the following purified antibodies for capture: anti-
mouse IL-1a (ALF-161), IL-6 (MP5-20F3) (both
eBioscience, San Diego, CA) and anti-mouse-VEGF
(BAF493, R&D Systems). For detection, we used biotin
anti-mouse IL-1 a (Polyclonal), IL-6 (MP5-32C11) and
biotin anti-mouse VEGF (AF-493-NA, R&D Systems) at
1 μg/well. Standard curves were constructed using
recombinant murine IL-1a (220-11), IL-6 (216-16) and
VEGF (450-32) (all Peprotech). Murine FGF was evalu-
ated in culture supernatants by using the Human FGF-
basic ELISA Development Kit (Peprotech) which cross-
react 100% with mouse. Each dilution of recombinant
standard or sample was assayed in duplicate. The reac-
tion was developed by using streptavidin-horseradish
peroxidase (554066, BD Pharmingen) and the 2,2’-azino-
di-[3-ethylbenzthiazoline sulfonate(6)] (ABTS) substrate
system (Roche Diagnostics GmbH, Mannheim, Ger-
many). The blue-green color produced by enzymatic
activity was quantified at 405 nm in an ELISA microplate
reader (Multiskan RC, ThermoLabsystems).
Proliferation assays
Murine myeloid C57BL/6 DCs recovered from long-
term cultures and treated for 48 h with an inflammatory
cocktail as described above were seeded in 96-well
round-bottom plates at a concentration of 1 × 10
5/well
in RPMI containing 10% FBS. Spleens were resected
from healthy BALB/c mice and minced in a sterile fash-
ion to yield a single cell suspension and erythrocytes
were eliminated by hypotonic shock. Then untouched
CD3 T cells were purified from this suspension by mag-
netic sorting using the Pan T Cell Isolation Kit (MACS
Miltenyi) following the manufacturer’s instructions. T
cells were labeled with CFSE as previously described
[25] and were incubated at a concentration of 1 × 10
5
cells/well with the recovered DCs for 5 days. CFSE dilu-
tion, an indication of cell proliferation, was assessed by
qualitative flow cytometry analysis of gated CD3 T cells.
Statistical analysis
For multiple comparisons we performed ANOVA analy-
sis with post-analysis by the Tukey-Kramer multiple
comparisons test or the Dunnett’s post comparison test.
A value of p < 0.05 was considered significant. Data are
expressed as mean ± SD. Data was analyzed by using
the Graph Pad Instat software (GraphPad Software, Inc.,
San Diego, CA).
Results
Expression of adhesion molecules by myeloid DCs
In the studies reported herewith, we used murine bone
marrow-derived (myeloid) DCs. Figure 1A depicts mye-
loid DCs showing typical dendrites at the end of their 8-
day differentiation culture from bone marrow precursors.
As determined by qualitative flow cytometry analysis
(Figure 1B), these cells are characterized by the expres-
sion of CD45 (not shown), b2 integrins CD11c and
CD18, and the myeloid marker CD11b while lacking
expression of CD8a molecule (not shown) usually pre-
sent in murine splenic DCs. We also investigated the
expression of MHC-II and members of the costimulatory
B7/CD28 (B7-1/2[CD80, CD86], and PDL-1/2) and the
TNF/TNF receptor (CD40, OX40L, and CD137) families.
As shown in Figure 1B, the immature cells express low to
null levels of surface costimulatory molecules CD86,
CD40 and CD137 when compared to the isotype con-
trols, while expressing higher levels of MHC-II, CD80,
PDL-1 and PDL-2/B7-DC. All these molecules are upre-
gulated upon activation (not shown). These molecules
can participate either in activation (CD80, CD86, CD40,
CD137, and OX40L) or suppression (PDL1/2) of T cell
activity [26], being the final effect a result of the interplay
between these sets of costimulators and coinhibitors. In
addition, by means of flow cytometry analysis we were
also able to detect, in the surface of these cells, the
expression of different adhesion molecules that partici-
pate in interactions with otherl e u k o c y t e so re n d o t h e l i a l
cells such as CD44, CD54 or PSGL-1 [27,28].
Murine myeloid(m) DCs have been extensively used in
order to determine the efficacy and improvement of DC-
based vaccines; investigate DC:T cell interactions or DC
development; and determine their role in pathological
conditions such cancer or infectious diseases [29-36].
Thus, we decided to use them as a model for our studies.
We have previously reported that these cells exhibit high
plasticity, being capable of acquiring angiogenic proper-
ties in vivo under pathological conditions [12]. We
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presence of specific cytokines or growth factors in their
microenvironment, but also by their physical interaction
with different surfaces such as those generated by deposi-
tion of extracellular matrix (ECM) components. To
investigate this we performed a series of studies in order
to determine the influence of adhesion surfaces on the
biology of DCs. First, by means of qualitative PCR analy-
sis we studied at the level of RNA the expression of adhe-
sion molecules capable of interacting with ECM
components. In particular we investigated the expression
of CD29 (binds with CD49 isoforms to generate adhesion
complexes), CD49a (CD49a\CD29 complex binds to
laminin and collagen), CD49b (CD49b\CD29 complex
binds to collagen and laminin), CD49c (CD29\CD49c
complex binds to laminin, collagen, fibronectin and
thrombospondin), CD49d (CD49d\CD29 complex binds
to fibronectin, and cellular components VCAM and
MadCam), CD49e (CD49e\CD29 complex binds to fibro-
nectin), CD49f (CD49f\CD29 complex binds to laminin),
CD41 and CD61 (CD41/CD61 complex binds to fibrino-
gen, fibronectin and vitronectin), and CD51 (CD51/
CD61 complex mediates adhesion to fibrinogen, fibro-
nectin, vitronectin and thrombospondin) [37]. As shown
i nF i g u r e1 C ,w ew e r ea b l et od e t e c te x p r e s s i o no ft h e s e
m o l e c u l e si nm D C sa tt h el e v e lo rR N A .I nas e r i e so f
complementary studies, we decided to investigate the
expression of these molecules at the level of protein. To
accomplish this we performed a direct staining of surface
mDC molecules using fluorescent antibodies and we ana-
lyzed the cells qualitatively by means of flow cytometry.
As shown in Figure 1D, immature mDCs express detect-
able levels of surface CD29, CD49d, CD49e, CD49f and
CD51 at the level of protein when compared to the iso-
type controls. Contrary to what we observed at the level
of RNA, we detected very low to null expression of
CD49a, CD41 and CD61 in the same cells by flow cyto-
metry analysis using direct staining. We cannot discard
that these molecules are expressed at very low levels on
the surface of the cells and require more sensitive
B A
C D
CD44 CD11b CD18
CD80 MHC-II CD86 CD40 B7-DC
CD54
S
S
C
FSC
S
S
C
CD11c
OX40L PDL-1
PSGL-1
CD49a CD49b
CD49d
CD29
CD49e CD49f
CD41 CD51 CD61
CD137
Figure 1 Immature mDCs express an array of adhesion molecules capable of interacting with ECM components.( A) Microphotograph of
mDCs upon differentiation from bone marrow precursors (20 × magnification). (B) Qualitative flow cytometry analysis of costimulatory molecules
and adhesion molecules to leukocytes or endothelial cells in immature myeloid DCs. Grey histograms represent isotype controls. An experiment
representative of 3 independent experiments is depicted. (C) PCR qualitative analysis of adhesion molecules to ECM components in immature
mDCs. An experiment representative of 3 independent experiments is shown. (D) Qualitative flow cytometry analysis of adhesion molecules to
ECM components in immature myeloid DCs. Grey histograms represent isotype controls. An experiment representative of 3 independent
experiments is depicted.
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flow cytometry.
Altogether these data indicate that similar to what has
been reported in the human [38-40], murine mDCs
express an array of adhesion molecules capable of inter-
acting with ECM components.
Generation of DC cultures on different surfaces and
media
We have previously shown that murine mDCs could be
cultured on Matrigel in the presence of tumor factors for
long periods of time [12]. Similar studies were performed
with human DCs grown on fibronectin and treated with
tumor factors [41]. In order to investigate the role of dif-
ferent surfaces on the biology of mDCs, we cultured
these cells on plates coated with fibronectin, collagen I,
gelatin, Matrigel, poly-D-Lysine (a synthetic polymer
which displays uniform net positive charges on the adhe-
sion surface), or regular plastic culture surfaces (polystyr-
ene) for up to 3 weeks. Also, to determine the effect of
different environmental conditions, we cultured these
cells in regular DC medium (RPMI) or endothelial cell
growth medium (EGM). Regular DC medium consisted
of RPMI medium supplemented with 10% FBS. The
EGM endothelial medium is supplemented with 10% FBS
together with several growth factors such as (human (h)
EGF, hydrocortisone, hVEGF, hFGF-B, hIGF-1, ascorbic
acid) that support endothelial cell proliferation.
Upon one week of culture in different conditions we
performed a qualitative photographic analysis of the
attached mDCs. As shown in Figure 2A, mDCs cultured
for a week with RPMI on different surfaces in the absence
of any maturation stimuli did not show the typical dendri-
tic prolongations usually depicted by these cells (Figure
1A). On the contrary, when cultured in the presence of an
inflammatory cocktail composed by 100 ng/ml of LPS +
20 ng/ml of TNFa, we observed a dramatic decrease in
the number attached cells and also a change in the shape
of the cells that remained attached, a great proportion of
which showed an elongated shape (Figure 2B). Interest-
ingly, this was not observed when cells were grown on
Matrigel-coated surfaces. Similarly, when cultured 1 week
with EGM, DCs also lose their typical shape (Figure 3A),
but the effects of inflammatory stimuli on the morphology
1 week RPMI
1 week RPMI in inflammatory conditions
A
Collagen Fibronectin Gelatin Matrigel Poly-D-
Lysine
Polystyrene
Collagen Fibronectin Gelatin Matrigel Poly-D-
Lysine
Polystyrene
Figure 2 Qualitative analysis of 1-week mDC cultures on different surfaces. Representative microphotograph of mDCs after 1 week of
culture with RPMI on different surfaces in the absence (A) or presence (B) of 100 ng of LPS and 20 ng/ml TNFa (20 × magnification). Two to 5
independent experiments were performed.
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that when cells were cultured in the presence of RPMI
(Figure 3B).
Phenotypical analysis of DCs upon culture on different
surfaces and media
In order to further determine the effect of different cul-
ture conditions on the biology of mDCs, we evaluated
the expression of costimulatory molecules by qualitative
flow cytometry analysis on CD11c gated cells. As
depicted in Figure 4, mDCs cultured with RPMI on dif-
ferent surfaces for 1 week in non-inflammatory condi-
tions showed lower expression of costimulatory
molecules CD80 and MHC-II as compared with the ori-
ginal population (Figure 1B). When the cells were cul-
tured in the presence of an inflammatory cocktail they
upregulated the expression of MHC-II and CD80 mole-
cules. This was most evident when mDCs were cultured
on poly-D-lysine and polystyrene substrates. This sug-
gests that ECM components are able to impair the effect
of maturation factors on the expression of costimulatory
molecules by attached mDCs. Further, cells cultured on
Matrigel, which showed little change in their morphology
when treated with inflammatory molecules, showed no
upregulation of costimulatory molecules as determined
by flow cytometry analysis. Similarly, mDCs cultured
with EGM also showed low levels of costimulatory mole-
cules, but contrary to what happened when cells were
cultured with RPMI, we were not able to observe upregu-
lation of costimulatory molecules in the presence of
inflammatory molecules (Figure 5).
In a series of complementary studies, we investigated
the supernatants of these cells for inflammatory cyto-
kines and nitrites. Upon treatment with LPS and TNFa,
mDCs are able to generate inflammatory molecules such
as IL-6 and IL-1a, and to upregulate the expression of
nitric oxide synthase-II, which generates nitric oxide. As
shown in Figure 6A-C, mDCs cultures treated with an
inflammatory cocktail generate statistically significant
higher levels of IL-6, IL-1a and nitrites (a subproduct of
nitric oxide metabolism) than untreated controls. Alto-
gether, these data indicate that these mDCs retained
their capability to respond to immune stimulation by
producing inflammatory molecules, even though they
showed low levels of costimulatory molecules (i.e. in the
presence of EGM).
1 week EGM
1 week EGM in inflammatory conditions
A
Collagen Fibronectin Gelatin Matrigel Poly-D-
Lysine
Polystyrene
Collagen Fibronectin Gelatin Matrigel Poly-D-
Lysine
Polystyrene
Figure 3 Qualitative analysis of 1-week mDC cultures on different surfaces. Representative microphotograph of mDCs after 1 week of
culture with EGM on different surfaces in the absence (A) or presence (B) of 100 ng of LPS and 20 ng/ml TNFa (20 × magnification). Two to 5
independent experiments were performed.
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Taking into account previous data showing that DCs
associated with pathological conditions are able to pro-
duce angiogenic factors [13,41] we decided to investigate
the presence in our cultures of VEGF and basic fibro-
blast growth factor (FGF) which have been reported to
participate in angiogenic processes [42-45]. In multiple
experiments we were always able to detect in all our
c u l t u r e st h ep r e s e n c eo fm u r i n eV E G Fb ym e a n so f
ELISA analysis (Figure 7A). Although we were not able
to detect significant differences in VEGF levels among
the different surfaces conditions within the EGM or
RPMI group (non-significant as determined by ANOVA
analysis followed by Tukey-Kramer Multiple Compari-
sons) we were able to determine that as a whole, the
RPMI cultures expressed higher VEGF levels than the
EGM groups (p = 0.039). We considered that this is due
to the presence of human VEGF in EGM cultures which
can interact with murine VEGF receptors [46] and
might downregulate the expression of this molecule by
these cells. We also investigated the presence of FGF in
our cultures. In this case, since the ELISA kit used for
our studies is able to detect the human FGF present in
the EGM medium, only samples taken from RPMI cul-
tures were used. As shown in Figure 7B, we detected
the expression of FGF in 1-week mDCs cultures. As
Collagen
Fibronectin
Gelatin
Matrigel
Poly-D-
Lysine
Polystyrene
MHC-II CD80
RPMI (CD11c gated)
MHC-II CD80
Inflammatory conditions
Figure 4 Expression of surface markers on mDCs cultured for 1 week on different surfaces with RPMI media in the presence or
absence of inflammatory factors. Cells were recovered from different cultures and analyzed by qualitative flow cytometry. Analysis was
performed on CD11c gated cells. Grey histograms represent isotype controls. The experiment was repeated 2 to 5 times with similar results.
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Page 8 of 22determined by ANOVA analysis, only cells cultured in
Matrigel generate significantly higher levels of FGF (p <
0.05) than the polystyrene control. Altogether these data
indicate that mDC cultures are able to generate angio-
genic factors.
Finally, DCs cultured for one week on different sur-
faces and media conditions express CD54 as determined
by comparison with isotype controls in a qualitative
flow cytometry assay (Figure 7C). This molecule has a
crucial role in the clustering of DCs with lymphocytes
by interacting with LFA-1 on the surface of T cells [47].
This indicates that these mDCs are able to interact with
T cells although not being capable of positively activat-
ing them due to low levels of costimulatory molecules.
Relevance of GM-CSF on the phenotype of DC cultures
In our previous experiments both RPMI and EGM cul-
tures were supplemented with external GM-CSF. Mye-
loid DCs obtained in vitro through the method
described by Lutz [16] are differentiated from bone mar-
row precursors in the presence of GM-CSF (20 ng/ml).
In our studies, after 1 week of culture in the absence of
GM-CSF few mDCs remained attached to the different
surfaces (Figure 8A and 8B) as determined by qualitative
micro-photographic analysis. These cells did not spread
on the culture surface as their GM-CSF-treated counter-
parts, but rather adopt a circular shape. Further, it was
not possible to generate 2 or 3-weeks cultures with
enough attached cells for analysis. Then, we decided to
Collagen
Fibronectin
Gelatin
Matrigel
Poly-D-
Lysine
Polystyrene
MHC-II CD80
EGM (CD11c gated)
MHC-II CD80
Inflammatory conditions
Figure 5 Expression of surface markers on mDCs cultured for 1 week on different surfaces with EGM media in the presence or
absence of inflammatory factors. Cells were recovered from different cultures and analyzed by qualitative flow cytometry. Analysis was
performed on CD11c gated cells. Grey histograms represent isotype controls. The experiment was repeated 2 to 5 times with similar results.
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Page 9 of 22investigate the expression of different surface immune
molecules in these cells by qualitative flow cytometry
analysis. In particular, we analyzed the expression of
CD11c, CD11b and GR1, and costimulatory molecules
MHC-II and CD80 in 1-week RPMI and EGM cultures
supplemented or not with GM-CSF. As described by
Lutz [16], when mDC cultures are extended for more
than 10 days after bone marrow collection, a decrease in
the levels of GM-CSF is recommended. For our studies
we used a GM-CSF concentration of 3 ng/ml [16]. As
depicted in Figure 9, mDCs cultured with RPMI in the
presence or absence of GM-CSF showed little modifica-
tion in the expression of CD11c and CD11b as deter-
mined by qualitative flow cytometry analysis. On the
other hand, the expression of costimulatory molecules
was low in the absence of GM-CSF as determined by
dot plot analysis of MHC-II and CD80 markers. The
proportion of cells expressing simultaneously both mar-
kers ranged from 8 to 29% in different conditions, as
determined by quadrants defined using isotype controls.
Similar results were obtained when cells were cultured
with EGM in the absence of GM-CSF. It is interesting
to comment that mDCs cultured with EGM in the pre-
sence or absence of GM-CSF decreased the levels of
CD11b expression, a typical myeloid marker (Figure 10)
when compared with similar cells cultured with RPMI
(Figure 9). Further, cells cultured in the presence of
EGM also showed a decrease in the expression of
CD11c (Figure 10). This was more evident when GM-
CSF was not present in the culture medium. This sug-
gests that in a context such as the tumor microenviron-
ment which is rich in angiogenic factors, cells that were
originally mDCs, might lose particular markers, thus
being overlooked when the tumor-associated leukocyte
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Figure 6 One-week mDC cultures response to inflammatory stimuli.I L - 6( A), IL-1a (B) and nitrites (C) were detected by ELISA analysis on
mDC-cultures after 1 week culture in the presence or absence of 100 ng/ml LPS and 20 ng/ml TNFa. An experiment representative of two
independent experiments with n = 2 for each condition is shown. (A) IL-6 production by DC cultures. All inflammatory stimuli-treated samples
showed significantly higher levels of nitrites when compared to their untreated counterparts as determined by ANOVA analysis followed by
Tukey-Kramer Multiple Comparisons post-test. *p < 0.001. (B) IL-1a production by DC cultures. All inflammatory stimuli-treated samples showed
significantly higher levels of nitrites when compared to their untreated counterparts as determined by ANOVA analysis followed by Tukey-Kramer
Multiple Comparisons post-test. *p < 0.001. (C) Nitrite detection by the Griess method. All inflammatory stimuli-treated samples showed
significantly higher levels of nitrites when compared to their untreated counterparts as determined by ANOVA analysis followed by Tukey-Kramer
Multiple Comparisons post-test. *p < 0.001.
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Page 10 of 22population is analyzed. Furthermore, only in cells cul-
tured with EGM we were able to detect the expression
of GR1 beyond control isotype levels, thus indicating
that part of the original mDC population could now co-
express CD11b and GR1 markers, typical of myeloid
derived suppressor cells, which have been detected in
tumor settings orchestrating antitumor immune
responses [48]. On the other hand, no GR1 expression
w a so b s e r v e dw h e nm D C sw e r ec u l t u r e dw i t hR P M I ,
independently of the surface assayed (Figure 9) as deter-
mined by qualitative flow cytometry analysis.
Generation of GM-CSF by ovarian cancer cells and its
effect on mDC phenotype
We have previously reported that mDCs can be cultured
for more than one week in ovarian cancer conditioned
medium [12]. We speculated that the tumor medium
could be a source of GM-CSF which can promote survi-
val of mDCs. Thus, we examined the capability of
mouse ovarian cancer cells to produce GM-CSF. As
shown in Figure 11A, mouse ovarian cancer cells
expressed GM-CSF at the level of RNA as determined
by qualitative PCR analysis. Further, we decided to
investigate if whole tumors could be a source of GM-
CSF in vivo. To accomplish this, mouse ovarian tumors
were developed in C57BL/6 mice, dissected and RNA
was extracted from whole tumor samples and analyzed
by real-time quantitative PCR. As determined by
ANOVA analysis followed by Dunnett post-comparison
tests, we were able to determine that all tumor samples
except one expressed GM-CSF at levels that were not
significantly different from those observed in normal
A
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p=0.039 B
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p<0.05
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ns
ns
ns
EGM (CD11c gated)
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Figure 7 One-week mDC cultures express angiogenic molecules.( A) VEGF was detected by ELISA analysis on mDC-culture supernatants. The
ELISA assay specifically recognized murine VEGF. Data from 5 independent experiments (n = 2 for each condition in every experiment) were
pooled for this analysis. No significant differences were obtained in the EGM or RPMI groups as determined by ANOVA analysis. However the
EGM group as a whole showed significantly lower VEGF levels than the RPMI group as determined by ANOVA analysis. (B) FGF ELISA analysis of
RPMI cultures. Variable expression of this molecule was observed in repeated experiments. Being the ELISA assay able to recognize human FGF,
a component of the EGM media, only RPMI supernatants were evaluated. Data from 5 independent experiments (n = 2 for each condition in
every experiment) were pooled for this analysis. Only gelatin cultures showed significantly higher levels of FGF when compared to the
polystyrene control as determined by ANOVA analysis followed by Dunnett’s post comparison test. (C) CD54 expression in 1-week cultures. A
qualitative flow cytometry analysis was performed in order to determine the expression of CD54 in the surface of these cells. The experiment
was repeated 3 times with similar results. Grey histograms represent isotype controls.
Sprague et al. BMC Immunology 2011, 12:35
http://www.biomedcentral.com/1471-2172/12/35
Page 11 of 22murine spleen, an immunological organ used as a con-
trol in these studies (Figure 11B). Production of GM-
CSF by mouse ovarian tumors might help interpret the
heavy DC infiltration observed in this tumor model (Fig-
ure 11C) [12]. To further investigate the relevance of
tumor-derived GM-CSF on mDCs we cultured these
cells with supernatants containing 30% of tumor condi-
tioned medium (30% v/v; ID8-VegfA tumor conditioned
medium:RPMI). Since tumor conditioned medium har-
bors other growth factors such as M-CSF and G-CSF
(not shown), as a control we treated some cultures with
anti-GM-CSF receptor antibody as previously described
[22]. mDCs cultured with RPMI plus 3 ng/ml of GM-
CSF on fibronectin and polystyrene attached and spread
on these surfaces (Figure 11D) as determined by qualita-
tive micro-photographic analysis. As described above,
this phenotype is lost in the absence of GM-CSF. Cells
cultured with tumor conditioned medium in the absence
of externally added GM-CSF attached and spread on
both surfaces, showing a phenotype that is close to
those of cells cultured with normal medium in the pre-
sence of GM-CSF. When an anti-GM-CSF receptor
antibody was added on day 1 of culture, we were able to
detect a lower number of attached cells, which showed a
phenotype that resembled those cells cultured in normal
medium in the absence of GM-CSF as determined by
qualitative micro-photographic analysis. These data indi-
cate that GM-CSF present in the tumor condition
medium contributes to promote attaching and spreading
of mDCs on different surfaces. Similar to what hap-
pened when these cells were cultured in EGM, tumor
conditioned medium abrogated the expression of CD11c
by mDCs to isotype levels as determined by qualitative
flow cytometry analysis (Figure 12).
Similarly, blocking the effect of tumor-derived GM-
CSF decreased the levels of costimulatory molecules in
these cells, as determined when comparing the propor-
tion of cells expressing both markers in anti-GM-CSFR
treated and control samples. This indicates that the pre-
sence of this molecule in the tumor microenvironment
might help preserve mDC function.
Angiogenic properties of long-term DC cultures
In this series of studies we decided to investigate if after 3
week in culture mDCs were able to produce angiogenic
factors. To accomplish this we analyzed, by means of
real-time PCR, the expression of several angiogenic mole-
cules previously described in APCs. In particular, we
evaluated the expression of VEGF-A 164 (which is the
predominant VEGF-A isoform) [44], hepatocyte growth
factor (HGF) [49], Heparanase [50], TWEAK [51,52] and
matrix metalloproteases (MMPs) 2 and 9 [53]. As con-
trols we used the same cells before culture (pre-culture
DCs) and we also include for comparison H5V, a murine
endothelial cell line [54]. As shown in Figure 13A, cells
cultured in the presence of EGM on fibronectin, collagen,
1weekRPMIwithoutGMͲCSF
1weekEGMMediawithoutGMͲCSF
A
B
Collagen Fibronectin Gelatin Matrigel Poly-D-Lysine
Collagen Fibronectin Gelatin Matrigel Poly-D-Lysine
Polystyrene
Polystyrene
Figure 8 Qualitative analysis of mDC attachment to different surfaces in the absence of GM-CSF. Microphotograph of mDCs after 1 week
of culture on different surfaces in EGM (A) and (B) RPMI in the absence of GM-CSF. The experiment was repeated 4 times with similar results. (20
× magnification)
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Page 12 of 22gelatin, poly-D-lysine and polystyrene showed a signifi-
cant decrease in the expression of VEGF as compared
with pre-culture DCs (ANOVA analysis followed by
Dunnett post comparison test). This was not observed
when cells were cultured with RPMI (Figure 13B). This
correlates with the decrease in VEGF protein levels
observed in one week EGM cultures when compared to
RPMI cultures (Figure 7A). We were also able to detect
an increase in HGF RNA levels in mDCs cultured with
EGM on fibronectin, collagen and poly-D-lysine. Finally,
EGM cultures in Matrigel also expressed significantly
higher levels of MMP2 and MMP9 at the level of RNA.
On the other hand, upon ANOVA analysis we were not
able to detect almost any significant differences respect
to pre-culture mDCs on cells cultured with RPMI. The
only exception being the expression of MMP-2, whose
expression was significantly higher (p < 0.05) in every
condition when compared to pre-culture cells. Finally, we
decided to include H5V, a murine endothelial, cell line
for comparison in our studies. As shown in Figure 13A,
the expression of several angiogenic molecules by H5V
was similar to what was detected in pre-culture DCs,
being the exception the expression of HGF which was
significantly lower in these endothelial cells. This similar
behavior between H5V and pre-culture mDCs highlights
the angiogenic potential of these APCs.
In a complementary series of studies, we analyzed by
qualitative PCR the presence of additional angiogenic fac-
tors and receptors in these cells. As shown in Figure 14A
and 14B, we detected expression of VEGF B and C, and
PIGF in all our samples, even on pre-cultured DCs at the
level of RNA. Further, these cells expressed VEGFR-1 and
-2 at the level of RNA (receptors for VEGF 164, VEGF-B
and PIGF) suggesting that they can be involved in auto-
crine loops. Finally, TIE-2, a receptor for angiopoietin and
associated with angiogenic leukocytes [55] was detected at
the level of RNA in pre-cultured cells and in some of the
cultured cells.
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Figure 9 GM-CSF and mDC expression of surface molecules by cells cultured with RPMI.M y e l o i dD C sw e r ec u l t u r e df o r1w e e ko n
different surfaces in RPMI in the presence or absence of 3 ng/ml of GM-CSF. Attached cells were recovered and the expression of CD11c,
CD11b, GR1, MHC-II and CD80 analyzed by qualitative flow cytometry. An experiment representative of 2 to 5 independent experiments is
shown. Grey histograms represent isotype controls. Quadrants in dot plot graphs were defined using isotype controls.
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Page 13 of 22Immunological capabilities of DCs upon long-term
cultures
Herewith we decided to focus our studies on the
immune properties of mDCs cultured for 3 weeks with
EGM on different surfaces. The rationale being that in
previous studies endothelial medium seemed to skew
the cells farther away from a typical immunostimulatory
DC phenotype [56,57]. As shown in Figure 15A, in
some of the experimental conditions, 3-week DC cul-
tures on different surfaces with EGM medium showed
little morphological resemblance with the original popu-
lation (Figure 1A) as determined by qualitative micro-
photographic analysis. In order to define the immunolo-
gical properties of these mDCs we isolated CD11c posi-
tive cells from the cultures by means of magnetic
sorting and cultured equal amounts of live cells in regu-
lar culture plastic plates (polystyrene) for 24 h (Figure
15B) before inducing maturat i o n .T oa c c o m p l i s ht h i s ,
cultures were treated with a typical inflammatory
cocktail (100 ng/ml of LPS + 20 ng/ml of TNFa)f o r
48 h. As shown in Figure 16A and 16B, we were able to
detect different levels of inflammatory cytokines IL-1a
and IL-6 in our cultures in response to stimulation. In
particular, very low levels of those molecules were pro-
duced by CD11c cells recovered from collagen cultures,
while CD11c recovered from Matrigel or poly-D-Lysine
cultures produced cytokine levels similar to those
obtained by fresh DCs. In the same way, when analyzing
the expression of CD80, a typical costimulatory mole-
cule, we observed that only CD11c cells recovered from
Matrigel and poly-D-Lysine cultures seemed to upregu-
late the expression of this molecule (Figure 16C) as
determined by qualitative flow cytometry analysis.
To further determine the immune capabilities of these
cells, after stimulation with an inflammatory cocktail we
cocultured them with CFSE-stained allogeneic BALB/c T
lymphocytes. Consistently with the ELISA and FACS data,
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Figure 10 GM-CSF and mDC expression of surface molecules by cells cultured with EGM. Myeloid DCs were cultured for 1 week on
different surfaces in EGM in the presence or absence of 3 ng/ml of GM-CSF. Attached cells were recovered and the expression of CD11c,
CD11b, GR1, MHC-II and CD80 analyzed by qualitative flow cytometry. An experiment representative of 2 to 5 independent experiments is
shown. Grey histograms represent isotype controls. Quadrants in dot plot graphs were defined using isotype controls.
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Page 14 of 22cultures induce higher levels of proliferation of allogeneic
T cells than cells recovered from other conditions (Figure
16D). Indeed, CD11c recovered from collagen cultures,
which produce the lowest levels of inflammatory cytokines
upon stimulation, were unable to induce proliferation of T
cells as determined by qualitative flow cytometry analysis.
Altogether, these data indicate that the interaction with
different surfaces affect in different ways the immunologi-
cal properties of mDCs.
Discussion
DCs present in peripheral tissues sample the organism for
the presence of antigens, which they take up, process and
present in their surface in the context of MHC molecules.
Typically, antigen-loaded DCs migrate to immunological
organs where they present the processed antigens to T
lymphocytes thus triggering specific immune responses.
On the other hand, a role of DCs as promoters of angio-
genesis under pathological conditions has been suggested
[13,15,58,59]. Our hypothesis is that in the tumor micro-
environment, this phenotypic shift is caused by the com-
bined effect of cytokine/growth factor signaling and
interaction with ECM components.
We and others have shown that monocytes or DCs can
undergo an endothelization process in vitro characterized
by the loss of CD14/CD45 and upregulation of endothelial
markers such as CD31, CD34, von Willebrand factor,
VEGF receptor (VEGFR)-2 and VE-Cadherin [12,41,60].
These cells can display other characteristics of bonafide
endothelium such as LDL uptake, lectin binding or
Fibronectin
Polystyrene
GM-CSF
no GM-CSF
30% tumor supernatant
anti-GM-CSFR Isotype control
A B C CD11c Isotype
D
GM-CSF
*
Figure 11 Tumor-derived GM-CSF and mDC cultures.( A) Expression of GM-CSF by mouse ovarian tumor cells at the level of RNA as
determined by qualitative PCR. An experiment representative of 2 independent experiments is shown. (B) Expression of GM-CSF by several
mouse ovarian tumors at the level of RNA as determined by quantitative real time PCR. Samples were analyzed in quadruplicate. All samples
except tumor 7 (* p < 0.05) expressed GM-CSF at levels that were not significantly different from those detected in spleen, an immune organ
that was used as a control for these studies. (C) Staining of mouse ovarian tumors shows heavy DC infiltration. Immunohistochemistry analysis
(200 × magnification). A photograph representative of 8 stained tumors is depicted. (D) Myeloid DCs were cultured on polystyrene and
fibronectin in the presence of RPMI supplemented or not with GM-CSF, and RPMI supplemented with 30% tumor conditioned medium without
addition of GM-CSF in the presence of anti-GM-CSF receptor antibody (4 μg/ml) or isotype control. (20 × magnification). An experiment
representative of 2 independent experiments with n = 2 is shown.
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Page 15 of 22formation of cord-like structures in 3D gels [12,24,
41,58,60,61]. DCs can also promote angiogenesis by gener-
ating angiogenic factors, i.e., DCs with proangiogenic
properties have been described in tumors and other patho-
logical conditions [15,58,62-64]. These data indicate that
DCs have a high plasticity, reacting to their microenviron-
ment by changing their morphology and biological activity.
This becomes important taking into account that it has
been postulated that the microenvironment where they
encounter their antigenic stimuli will define the outcome
of the DC:T cell interaction (Signal 3) and the consequent
immune response.
Several reports indicate that soluble factors can alter the
biology of DCs. Tumor-associated cytokines such as VEGF,
IL-10 and PGE-2 can profoundly affect the nature of APCs.
In particular, DCs showing low levels of costimulatory
molecules have been detected in tumors expressing high
levels of VEGF [65] and tumor patients treated with anti-
VEGF antibody showed a decrease in the levels of immu-
nosuppressive DCs [66]. In the same way, it has been
shown that the endothelial cell-produced antiangiogenic
cytokine vascular endothelial growth inhibitor induces DC
maturation [10]. Another molecule present in the tumor
microenvironment that can profoundly affect DC biology is
PGE-2. This molecule has been shown to induce the pro-
duction of IL-10 and VEGF by human DCs [8].
On the other hand, few studies have been undertaken
in order to determine the effect of different ECM
components on the biology of DCs. Foundational work
on this subject was performed on 1998 by Brand et al.
[39]. This research group, working with human mono-
cyte-derived DCs, investigated the adhesion of these cells
to collagen I, IV and fibronectin. They were able to show
that these cells adhere differentially to these ECM com-
ponents, rapidly changing their morphology when they
attached to fibronectin or increasing their maturation
status upon interaction with collagen I. In another series
of experiments, Ammon et al. [38] described the expres-
sion of different integrin receptors in human monocytes,
monocyte-derived DCs and macrophages. More recently
Kohl et al., [40] reported that human DCs derived from
CD34 precursors or from monocytes differentially bind
to ECM components, and display different expression of
surface integrins.
Herewith we report that attachment to a surface
together with factors provided in the media allowed
long-term mDC cultures to exhibit different immunolo-
gical capabilities. DCs are usually considered short-lived,
terminal cells whose main function is to activate T cells
in order to induce specific immune responses. We were
able to demonstrate that these cells need the presence of
GM-CSF in order to be able to establish long-term cul-
tures; that GM-CSF can be produced by ovarian cancer
c e l l sa n dt h a ti se x p r e s s e di nt h em i c r o e n v i r o n m e n to f
mouse ovarian tumors. In terms of the role of adhesion
surfaces on the biology of these cells, we were able to
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Figure 12 Expression of surface markers on mDCs cultured for 1 week in the presence of tumor factors. Myeloid DCs were cultured on
polystyrene and fibronectin in the presence of RPMI medium supplemented with 30% tumor conditioned medium without addition of external
GM-CSF and in the presence of anti-GM-CSF receptor antibody (4 μg/ml) or isotype control. Cells were recovered from cultures after 1 week and
analyzed by qualitative flow cytometry. Grey histograms represent isotype controls. Quadrants in dot plot graphs were defined using isotype
controls. An experiment representative of 2 independent experiments (n = 2 each experiment) is shown.
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Page 16 of 22show that cells cultured on different surfaces showed
expression of angiogenic molecules such as HGF, bFGF,
MMP2 and MMP9. We also showed that these cells are
able to produce VEGF-A, -B and PIGF. Taking into
account that most of these molecules were expressed in
every condition it is tempting to speculate that if mDCs
are not driven to initiate an immune response they will
by default remain in a proangiogenic state. Further, since
we were able to detect the expression of VEGFR-1 and -2
in these cells it is tempting to speculate that some of
A
B
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RPMI
* * * **
*
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* * *
*
*
Figure 13 Expression of angiogenic molecules from 3-week mDC cultures. DCs were recovered from different cultures after 3 weeks in
EGM (A) or RPMI (B), RNA was extracted and reverse-transcribed. Then, quantitative real-time PCR was performed to analyze several angiogenic
molecules in these cells. (A) As determined by ANOVA analysis followed by Dunnett multiple comparison test using pre-culture mDCs as a
control, expression of VEGF, HGF, MMP2 and MMP9 was significantly different under some conditions (* p < 0.05). (B) MMP-2 expression levels in
the RPMI cultured-group showed statistically significant differences respect to pre-culture mDCs at p < 0.05 as determined by ANOVA analysis.
For A and B, samples were run in duplicate in each experiment and further analyzed in duplicate by quantitative real-time PCR. An experiment
representative of 2 independent experiments is shown.
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Figure 14 Qualitative PCR analysis of angiogenic molecules expression by 3-week mDC cultures. DCs were recovered from different
cultures after 3 weeks in EGM (A) or RPMI (B), RNA extracted and reverse-transcribed. Then, qualitative PCR was performed to analyze
angiogenic molecules and receptors in these cells. An experiment representative of 2 independent experiments is shown.
3 weeks A
Collagen Fibronectin Gelatin Matrigel Poly-D-
Lysine
Polystyrene
Reseeded on polystyrene
Collagen Fibronectin Gelatin Matrigel Poly-D-
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B
Figure 15 Qualitative analysis of mDCs upon reattachment to plastic.( A) Microphotograph of mDCs after 3 weeks of culture on different
surfaces (20 × magnification). (B) Microphotograph of reattached DCs. Myeloid DCs cultured for 3 weeks on different surfaces with EGM were
detached, purified using CD11c magnetic beads and cultured on polystyrene for 24 h (20 × magnification). An experiment representative of 2
independent experiments is shown.
Sprague et al. BMC Immunology 2011, 12:35
http://www.biomedcentral.com/1471-2172/12/35
Page 18 of 22these angiogenic molecules might act in an autocrine
fashion, promoting cell survival or induction of other
angiogenic molecules. Finally, expression of MMPs by
DCs might promote VEGF availability [67] thus contri-
buting to angiogenic process but might also help degrade
ECM components facilitating metastasis in a tumor
setting.
In terms of immunological properties, we observed that
after 1 week culture in non-inflammatory conditions,
mDCs showed low levels of costimulatory molecules.
Attachment to the different surfaces did not inhibit the
capability of these cells to respond to inflammatory sti-
muli. In particular, these cells upregulated the expression
of costimulatory molecules, and produced IL-1a,I L - 6
and nitric oxide when cultured in the presence of LPS
and TNFa. This effect was less pronounced when cells
were cultured with EGM, indicating that the factors
present in this medium can decrease the effects of
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Figure 16 Immunological properties of 3-week mDC cultures in EGM.I L - 1 a (A) and IL-6 (B) were detected by ELISA on reseeded cultures
after 48 h stimulation with TNFa and LPS. (A) ANOVA analysis: p < 0.0001. Tukey-Kramer Multiple Comparisons post-Test: Fibronectin vs.
collagen, Matrigel, poly-d-lysine, polystyrene and preculture: p < 0.001; vs. gelatin: NS. Collagen vs. gelatin, Matrigel, poly-d-lysine, polystyrene,
and preculture: p < 0.001. Gelatin vs. Matrigel, poly-d-lysine, polystyrene, and preculture: p < 0.001. Matrigel vs. poly-d-lysine, polystyrene, and
preculture: p < 0.001. Poly-d-lysine vs. polystyrene, and preculture: p < 0.001. Polystyrene vs. preculture: p < 0.001. An experiment representative
of 2 independent experiments is shown. (B) ANOVA analysis: p < 0.0001. Tukey-Kramer Multiple Comparisons post-test: Fibronectin vs. collagen,
Matrigel, poly-d-lysine, polystyrene, and preculture: p < 0.001; vs. gelatin p < 0.01. Collagen vs. gelatin, Matrigel, poly-d-lysine, polystyrene, and
preculture: p < 0.001. Gelatin vs. Matrigel, poly-d-lysine, and preculture: p < 0.001; vs. polystyrene: p < 0.05. Matrigel vs. polystyrene, poly-d-lysine,
and preculture: p < 0.001. Poly-d-lysine vs. polystyrene: p < 0.001; vs. preculture: NS. Polystyrene vs. preculture: p < 0.001. An experiment
representative of 2 independent experiments is shown. An experiment representative of 2 independent experiments is shown. (C) Qualitative
flow cytometry analysis of CD80 in mDCs recovered from 3-week cultures before and after treatment with inflammatory factors. Grey histograms
represent isotype controls. Numbers represent mean fluorescence intensity values. An experiment representative of 2 independent experiments
is shown. (D). CFSE dilution analysis. Proliferation of CFSE-stained allogeneic BALB/c lymphocytes was determined by qualitative flow cytometry
analysis after 5 day co-culture with the same mDCs as in (C). An experiment representative of 2 independent experiments is shown. Numbers
represent percent of CFSE negative cells.
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Page 19 of 22inflammatory factors. Further, DCs cultured on different
surfaces for 3 weeks showed differential immunological
capabilities. In particular, DCs recovered from Matrigel,
(a gelatinous protein mixture purified from murine
tumor stroma) and from poly-D-Lysine (an artificial poly-
mer) were able to respond to maturation stimuli similarly
to fresh mDCs. Upon stimulation, these cells produced
large quantities of IL-1a and IL-6, and induced prolifera-
tion of allogeneic lymphocytes. On the other end, DCs
recovered from collagen I surfaces were completely unre-
sponsive to maturation stimuli.
Conclusions
Herewith we demonstrated that the combination of
soluble factors together with adhesion surfaces deter-
mines particular mDC profiles. Thus, in order to design
DC-based vaccines or treatments focused on changing
the phenotype of DCs associated with diseases, such as
cancer [68-70] or atherosclerosis [71,72] among others,
it becomes necessary to fully investigate the microenvir-
onment in which these cells are present or will be
delivered.
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